anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study investigates the effects of high dosage task and impairment based training of the hemiparetic hand, using haptic robots integrated with complex gaming and virtual reality simulations on recovery and function of the hand, when the training is initiated within early period of heightened plasticity. The intervention uses two training systems. NJIT-RAVR consists of a data glove combined with the Haptic Master robot that provides tracking of movements in a 3D workspace and enables programmable haptic effects, such as variable anti-gravity support, springs and dampers, and various haptic objects. The NJIT-TrackGlove consists of a robotic hand exoskeleton to provide haptic effects or assistance and an instrumented glove for finger angle tracking, and an arm tracking system to track hand and arm position and orientation. Using programmable software and custom bracing we enable use of this system for patients with a broad set of impairments and functional abilities. A library of custom-designed impairment and task-based simulations that train arm transport and hand manipulation, together or separately will be used. Pilot data show that it is possible to integrate intensive, high-dosage, targeted hand therapy into the routine of an acute rehabilitation setting. The study integrates the behavioral, the kinematic/kinetic and neurophysiological aspects of recovery to determine: 1) whether early intensive training focusing on the hand will result in a more functional hemiparetic arm; (2) whether it is necessary to initiate intensive hand therapy during the very early inpatient rehabilitation phase or will comparable outcomes be achieved if the therapy is initiated right after discharge, in the outpatient period; and 3) whether the effect of the early intervention observed at 6 months post stroke can be predicted by the cortical reorganization evaluated immediately prior to the therapy. This study will fill critical gaps in the literature and make a significant advancement in the investigation of putative interventions for recovery of hand function in patients post-stroke.
The plasma protein binding of lidocaine is dependent on drug concentration, and the fraction bound decreases with increasing concentration. At concentrations of 1 to 4 micrograms of free base per milliliter 60 to 80 percent of lidocaine is protein bound. Binding is also dependent on the plasma concentration of alpha-1-acid glycoprotein. 

Lidocaine crosses the blood-brain and placental barriers, presumably by passive diffusion.

Approximately 90% of lidocaine administered is excreted in the form of various metabolites, and less than 10% is excreted unchanged. Biotransformation includes oxidative N-dealkylation, ring hydroxylation, cleavage of the amide linkage, and conjugation. CYP1A2 and CYP3A4 mediated N-dealkylation, a major pathway of biotransformation, yields the metabolites monoethyl glycine xylidide (MEGX) and glycine xylidide (GX). The pharmacological/toxicological actions of these metabolites are similar to, but less potent than, those of lidocaine. The primary metabolite in urine is a conjugate of 4-hydroxy-2,6-dimethylaniline. The elimination half-life of lidocaine following an intravenous bolus injection is typically 1.5 to 2.0 hours.
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and is a leading cause of cancer-related death worldwide. The prognosis of HCC remains poor, with a 5-year survival rate of 18%. Risk factors for HCC include viral infection, autoimmune hepatitis, chronic alcohol use or metabolic fatty liver disease, obesity, and diabetes mellitus. Furthermore, alterations and chronic inflammation of the microenvironment can facilitate the transformation of normal liver stem cells into precancerous tumor stem cells. All these underlying pathogenic stimuli can induce a spectrum of genetic and epigenetic modifications, which are involved in the cell cycle, cell growth and regulation of adhesion. Therefore, heterogeneity and tumor priming potential arise from a combination of both endogenous and exogenous factors. However, current in vitro models, based on conventional hepatoma and hepatocarcinoma cell lines, fail to recapitulate key characteristics of tumor tissue such as three-dimensional tissue architecture, cellular heterogeneity, and cell-cell interactions. Organoids, which are 3D cellular structures generated from induced pluripotent stem cells and adult tissue-resident stem cells, have recently been exploited to overcome the limitations of 2D cell culture systems, emerging as powerful tools for studying human diseases. Therefore, organoid structures stably preserve the genetic information of autologous tissue by mimicking the pathological state of the tissue itself.
BACKGROUND/OBJECTIVES: Disease improvement for difficult-to-control pediatric atopic dermatitis may be more challenging to achieve when directed by single specialties due to disjointed and conflicting dialogue with patients.
METHODS: The Multidisciplinary Atopic Dermatitis Program (MADP) was developed through collaborations with the Rady Children's Hospital and UC San Diego Health Divisions of Dermatology, Allergy & Immunology and Clinical Pharmacy, to create team-based evaluation and management of children and adolescents with atopic dermatitis (AD). The MADP allows concurrent, comprehensive evaluations by multiple specialists to develop treatment plans. The program includes extensive patient education to support shared decision making, incorporating patient and family's perspectives along with those of clinical experts into their care. Objective severity measures and patient reported outcome data were collected, along with assessment of patient and family satisfaction with the MADP.
RESULTS: Data showed significant improvement in AD severity as assessed by providers, patients and families by the first follow-up visit. BSA mean percentage decreased by up to 56% by the 7th visit, and pruritus (NRS), CLDQI and POEM mean scores decreased by more than 4 points, 12 points, and over 11 points, respectively. After management was initiated in the MADP, 72.73% of patients achieved an EASI 50 and 47.73% achieved an EASI 75 from a baseline mean of 21.7. Patients who continued in clinic beyond the second visit showed further clinically significant decreases in disease measures.
CONCLUSIONS: The multidisciplinary approach shows success in the treatment of difficult-to-control AD patients with improvements in clinician and patient reported outcome measures.
<P>PROBLEM TO BE SOLVED: To provide a micro-particle zinc oxide dispersion affording a natural finish feeling with transparency and having excellent ultraviolet protecting effects in both the UVA and the UVB regions and good stability with time.  <P>SOLUTION: The micro-particle zinc oxide dispersion is characterized as dispersing micro-particle zinc oxide having 15-55 nm primary particle diameter into 70-140 nm average dispersed particle diameter in a hydrophobic dispersion medium. In the micro-particle zinc oxide dispersion, the content of the silicone oil is preferably 10-100 mass% based on the whole hydrophobic dispersion medium. A both terminal siliconated polyglycerol is further preferably contained as a dispersing agent in the micro-particle zinc oxide dispersion. The micro-particle zinc oxide dispersion can suitably be formulated in a cosmetic.  <P>COPYRIGHT: (C)2007,JPO&INPIT
PURPOSE:To provide a proliferation-promoting agent containing glucose-1- phosphoric acid, glucose-6-phosphoric acid or their salt and useful especially for promoting the regeneration of liver after hepatectomy. CONSTITUTION:The objective agent for promoting the proliferation of hepatocyte and used in the form of an injection is prepared by using at least one kind of compound selected from glucose-1-phosphoric acid, glucose-6- phosphoric acid or their salt (e.g. an alkali metal salt, especially Na salt) as an active component. The pH of the agent is maintained preferably to 3.0-8.0, especially 5.0-7.5 and the concentration of the active component compound is 1-30%(w/v), preferably 5-15%(w/v). The proper daily dose for adult is 10mg-30g. preferably 100mg-10g of the active component compound.
In the phase III clinical trials performed in support of once-daily dosing, 799 subjects with otitis externa and intact tympanic membranes were treated with ofloxacin otic solution. The studies, which served as the basis for approval, were 020 (pediatric, adolescents and adults), 016 (adolescents and adults) and 017 (pediatric). The following treatment-related adverse events occurred in two or more of the subjects.

An unexpected increased incidence of application site reaction was seen in studies 016/017 and was similar for both ofloxacin and the active control drug (neomycin-polymyxin B sulfatehydrocortisone). This finding is believed to be the result of specific questioning of the subjects regarding the incidence of application site reactions.

In once daily dosing studies, there were also single reports of nausea, seborrhea, transient loss of hearing, tinnitus, otitis externa, otitis media, tremor, hypertension and fungal infection.

In twice daily dosing studies, the following treatment-related adverse events were each reported in a single subject: dermatitis, eczema, erythematous rash, follicular rash, hypoaesthesia, tinnitus, dyspepsia, hot flushes, flushing, and otorrhagia.
PURPOSE: To explore pain experiences of children with cerebral palsy, and how it influences their everyday life.
METHOD: Fourteen children with CP between eight and seventeen years old were included, using a purposeful sampling strategy. They had different experiences of pain, and different degrees of physical and cognitive impairments. Sixteen individual semi-structured interviews were carried out, and analyzed using inductive thematic analysis.
RESULTS: Data analysis resulted in the main theme "I have to obey my pain" and four themes were identified. Experiences regarding pain varied ("My pain is mine alone"). Both pain itself and the use of cognitive strategies to cope with pain involved a mental struggle ("Pain brings me down"). The children had to make adjustments to manage their pain ("I want to participate, but I have to rest"). The most important help was to be understood, but adults also provided valuable help with interventions like stretching, medication and adjustment of activity levels ("Others can help me").
CONCLUSION: Pain was a determining feature in the lives of these children with CP. The wide variety of experiences and challenges emphasized the need for tailored management strategies developed together with each child and their parents.IMPLICATIONS FOR REHABILITATIONChildren with cerebral palsy had varied experiences of pain, and health professionals need to tailor their pain management approaches to the individual child.Health services should offer pain education to expand children's repertoire of pain management strategies.When a child's pain influences their daily activities, health services must ensure that the school is informed of the child's situation, and able to make necessary adjustments.Health professionals should strive to include children's own descriptions whenever possible to make sure children feel heard and believed.Even children with communicative and cognitive impairments were able to self-report when necessary adjustments in the communication situation were made.
17α-hydroxylase is a rare form of congenital adrenal hyperplasia. Patients with complete 17α-hydroxylase deficiency may come to attention to the doctor at their early adulthood due to hypertension or disordered puberty. 17α-hydroxylase is a form of cytochrome P450 enzyme in the adrenal cortex for the production of cortisol, while 17,20-lyase is required in both adrenal glands and the gonads for the production of androgen precursors of sex hormones. Therefore, patients with 17α-hydroxylase will presented with elevated deoxycorticosterone (DOC) level and decreased aldosterone and cortisol level. Because DOC is the second most important naturally occurring mineralocorticoid hormone, hypertension and hypokalemic alkalosis will be noted in these patients. Besides, deficiency of 17,20-lyase activity will lead to impairment of virilization in 46 XY patients and deficient estrogen production in 46 XX patients.

The P450c17 has both 17α-hydroxylase and 17,20-lyase activity and are encoded by the CYP17 gene. The sequence of CYP17 gene was established in 1987 and more than 40 mutations were identified till now. The purpose of this study is to elucidate the molecular pathology of the 4 families with 17α-hydroxylase/17,20-lyase deficiency.
The invention discloses an anti-aging skin care product, in particular to an essence containing umbilical cord mesenchymal stem cell secretin and a preparation method thereof, wherein the essence comprises the following components in percentage by weight: 10% -30% of umbilical cord mesenchymal stem cell secretin, 5% of glycerol, 5% of butanediol, 8% of schizosaccharomyces cerevisiae fermentation product lysate, 6% of glucan, 1% of hexapeptide, 1% of pentapeptide, 0.8% of sodium hyaluronate, 0.3% of preservative and the balance of sterile water. The more specific application method comprises the following steps: adding sodium hyaluronate, glycerin and butanediol into a stirring cylinder, stirring and heating to 50-60 ℃, and then keeping the temperature for 30 minutes. Adding the lysate of the yeast fermentation product of the second split, the glucan, the hexapeptide and the pentapeptide in no sequence, and stirring uniformly. Cooling to room temperature, adding umbilical cord mesenchymal stem cell secretin, and stirring to obtain essence. The advantages are that: the novel umbilical cord mesenchymal stem cell secretin is rich in umbilical cord mesenchymal stem cell secretin, has the functions of promoting activation, proliferation and renewal of epidermal stem cells and hair follicle stem cells, increasing collagen secretion, is very important for keeping skin elastic, compact and healthy, is safe and has no side effect. The essence provides a good method for delaying aging and restoring skin health.
A method for presenting health notifications begins with creating a plurality of different health notifications, each conveying the same type of information. Each of the different health notifications is provided to a plurality of different users, each user categorized with user health metrics. Post-health notification user activity is tracked for each of the different users. A machine-learning classification machine is trained with tracked user activity, along with corresponding user health metrics, for each of the different health notifications. When provided with user health metrics received from a health-monitoring computing device associated with a user, the machine-learning classification machine chooses a selected health notification for the user from among the different health notifications, the selected notification determined to be more likely than any of the other health notifications to elicit a healthy response from the user. The selected health notification is then sent to the user.
PURPOSE:To obtain the title preparation having an excellent feeling in adminis tration, various ready dosage forms, inexpensively producible, applicable depending upon patients, containing a specific polymer quaternary salt, specific strongly basic anion exchange resin and specific hydrophobic substance as active ingredients. CONSTITUTION:(A) A polymer quaternary salt shown by formula I (R1 is H, 1-17C alkyl, etc.; R2 and R3 are H or 1-3C alkyl; R4 is H or methyl; Y(-) is halogen, hydroxyl ion, etc.; n is >=1 integer; Ar is group shown by formula II, formula III, etc.; X is halogen or group shown by formula IV), (B) a strongly basic anion exchange resin which is a copolymer of a polyfunctional epoxy compound containing two or more oxirane rings and contains imidazolium salt having one selected from halogen ion, hydroxyl ion, etc., as a counter ion as a functional group and a hydrophobic substance are used as active ingredients. The amount of the hydrophobic substance used is preferably 2-100wt.% based on the anion exchange resin.
Patients will receive a 12-week lifestyle program during treatment. Patients will also receive maintenance support following the 12-week program.
Absorption of atovaquone may be reduced in patients with diarrhea or vomiting. If atovaquone and proguanil hydrochloride is used in patients who are vomiting, parasitemia should be closely monitored and the use of an antiemetic considered. [See Dosage and Administration ( 2).] Vomiting occurred in up to 19% of pediatric patients given treatment doses of atovaquone and proguanil hydrochloride. In the controlled clinical trials, 15.3% of adults received an antiemetic when they received atovaquone/proguanil and 98.3% of these patients were successfully treated. In patients with severe or persistent diarrhea or vomiting, alternative antimalarial therapy may be required.
Magnesium will be given intravenously with a loading dose of 4 g in 50 mL saline over a 15-minute period and 16 g in 100 mL over a 24-hour period in a continuous-infusion form. The regiment chosen for this study is designed to double serum magnesium concentration to twice physiological concentration for therapeutic effects in humans, Serum levels between 4.8mg/dl-6mg/dl are considered to have an optimal neuroprotective effect.
Participants will receive 7.4 GBq (200 mCi) +/- 10% 177Lu-PSMA-617 once every 6 weeks for 6 cycles. Best supportive care, including ADT may be used.
Slides were selected that contained clinically relevant histopathologic "features" that are generally encountered on surgical pathology slides. Twenty-one features, each selected from three different organs, were to be included to ensure that multiple tissue types were investigated. The study feature(s) as selected on each slide was defined as the "selected feature". In total 420 selected features were acquired and the slides holding these features composed the "slide set". The slideset consisted of 399 slides from 399 different participants.

1. Intra-system study. The full slide set was then divided over three subsets. Each subset was then scanned three times on one systems, with each subset being scanned on a different scanner. This means that each feature was scanned three times. Each of three pathologists read all three scans of the entire slide set. Intra-system precision was thereby determined.
2. Inter-system study. The full slide set was then scanned three times, each time on a different system, meaning that each feature was scanned three times. Each of three pathologists (different pathologists the ones used in the intra-system study) read all three scans of the entire slide set. Inter-system precision was thereby determined.
Recurrence risks of cancer patient can change during treatment as a result of treatment-related tumor evolution. However, biomarkers that can monitor these changes are lacking. Here, we investigated whether tracking circulating tumor DNA (ctDNA) dynamics through liquid biopsy can inform real-time recurrence risk. Nasopharyngeal carcinoma (NPC) provides an ideal model where cell-free Epstein-Barr virus (EBV) DNA (cfEBV DNA), a ctDNA, can be sensitively detected. We conducted the EP-SEASON study (NCT03855020) and prospectively recruited 1,000 NPC patients undergoing per-protocol cfEBV DNA assessments at 11 time points and receiving sequential chemo-radiotherapy. Longitudinal cfEBV DNA displayed distinct patterns during neoadjuvant chemotherapy and radiotherapy. Despite the prognostic significance of cfEBV DNA at each time point, real-time recurrence risks changed in sync with cfEBV DNA dynamics. Furthermore, we identified phenotypes of whole-course ctDNA changing dynamics associated with different survival outcomes. In conclusion, tracking longitudinal on-treatment ctDNA can forecast real-time recurrence risk, facilitating risk-adapted, individualized patient management.
The present invention relates to a pharmacokinetic-based design and selection tool (PK tool) and methods for predicting absorption of an administered compound of interest. The methods utilize the tool, and optionally a separately operable component or subsystem thereof. The PK tool includes as computer-readable components: (1) input/output system; (2) physiologic-based simulation model of one or more segments of a mammalian system of interest having one or more physiological barriers to absorption that is based on the selected route of administration; and (3) simulation engine having a differential equation solver: The invention also provides methods for optimizing as well as enabling minimal input requirements a physiologic-based simulation model for predicting in vivo absorption, and optionally one or more additional properties, from either in vitro or in vivo data. The PK tool of the invention may be provided as a computer system, as an article of manufacture in the form of a computer-readable medium, or a computer program product and the like. Subsystems and individual components of the PK tool also can be utilized and adapted in a variety of disparate applications for predicting the fate of an administered compound. The PK tool and methods of the invention can be used to screen and design compound libraries, select and design drugs, as well as predict drug efficacy in mammals from in vitro and/or in vivo data of one or more compounds of interest. The PK tool and methods of the invention also finds use in selecting, designing, and preparing drug compounds, and multi-compound drugs and drug formulations (i.e., drug delivery system) for preparation of medicaments for use in treating mammalian disorders.
In this study we examined how specific personality traits are related to psychosocial adjustment in people with intellectual disability. We studied 73 students with mild intellectual disability and 25 students with moderate intellectual disability who attended special schools in Poland. Personality traits were assessed with the Revised Edward Zigler-Yale Questionnaire (EZPQ-16R) and to assess adjustment we used a total-difficulties score in Strengths and Difficulties Questionnaire (SDQ). We hypothesized a predictive relationship between the specific personality traits and adjustment. The relation between personality and adjustment was stronger in people with moderate intellectual disability than in people with mild intellectual disability. In students with moderate intellectual disability the relation between personality and adjustment was significant for each of the studied traits and in students with mild intellectual disability it was significant for negative-reaction tendency, and assignment alacrity. Obtained results indicate that specific traits are important to adjustment of people with intellectual disability.
Patients receive cycles 5-13 of the MVI regimen as in STAGE III FHWT Arm IIA above. Patients also undergo CT, CT/MRI, ultrasound, X-ray, and bone scan/PET scans throughout the trial.